Live Analyst Rating Changes 24314 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Vamil Divan
GUGG

Vamil Divan

Guggenheim
Wall Street Analyst
★★★★☆
#374
on 13Foresight · ranked by our own returns
62%
Success Rate
+19.1%
Average Return
56 of 90 calls profitable · +13.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 62% of Vamil Divan's ratings turned a profit when each position was held for 1 year — averaging +19.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

128 Buy 7 Hold 0 Sell
Vamil's Stock Coverage 56 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SVRA
Savara
 Aug 11, 2026 BUY Strong Buy
+52.9% avg upside
17 analysts
$11.00
92.91% Upside
 -7.5% ·
JBIO
Jade Biosciences
 Aug 10, 2026 BUY Strong Buy
+146.6% avg upside
16 analysts
$47.00
102.53% Upside
 +9.6% ·
ANIP
ANI Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+36.1% avg upside
11 analysts
$119.00
58.37% Upside
 -4.2% ·
AMGN
Amgen
 Aug 07, 2026 HOLD Buy
-24.2% avg upside
57 analysts
$388.00
6.84% Downside
 +1.5% ·
INSM
Insmed
 Aug 06, 2026 BUY Strong Buy
+33.7% avg upside
37 analysts
$205.00
55.00% Upside
 -4.7% ·
PFE
Pfizer
 Aug 06, 2026 BUY Buy
+27.4% avg upside
45 analysts
$31.00
17.79% Upside
 +3.2% ·
TVTX
Travere Therapeutics
 Aug 05, 2026 BUY Strong Buy
-8.9% avg upside
22 analysts
$75.00
20.63% Upside
 -2.1% ·
JNJ
Johnson & Johnson
 Aug 05, 2026 BUY Strong Buy
-9.5% avg upside
39 analysts
$287.00
9.94% Upside
 +0.8% ·
MRK
Merck & Company
 Aug 04, 2026 BUY Strong Buy
-2.3% avg upside
43 analysts
$146.00
9.86% Upside
 +0.3% ·
ABBV
AbbVie
 Aug 03, 2026 BUY Strong Buy
-4.0% avg upside
46 analysts
$288.00
15.76% Upside
 +2.3% ·
VALN
Valneva
 Jul 21, 2026 BUY Strong Buy
+103.8% avg upside
6 analysts
$11.00
98.29% Upside
 +7.5% ·
ELOX
Eloxx Pharmaceuticals
 Jul 19, 2026 BUY Strong Buy
+97.4% avg upside
10 analysts
$43.00
135.41% Upside
 +50.8% ·
VERA
Vera Therapeutics
 Jul 08, 2026 BUY Strong Buy
+128.9% avg upside
19 analysts
$76.00
153.39% Upside
 -31.9% ·
SCYX
SCYNEXIS
 Jul 01, 2026 BUY Strong Buy
+165.9% avg upside
10 analysts
$3.00
37.60% Downside
 +14.4% ·
UNCY
Unicycive Therapeutics
 Jun 30, 2026 BUY Strong Buy
+894.5% avg upside
10 analysts
$37.00
586.40% Upside
 +13.0% ·
ABSI
AbSci
 Jun 25, 2026 BUY Strong Buy
+28.1% avg upside
18 analysts
$15.00
57.99% Upside
 -6.5% ·
ASMB
Assembly Biosciences
 May 28, 2026 BUY Strong Buy
+25.0% avg upside
10 analysts
$43.00
58.90% Upside
 -1.7% ·
SE:VICO
Vicore Pharma Holding AB
 May 06, 2026 BUY Strong Buy
+201.3% avg upside
2 analysts
$38.00
218.31% Upside
 +9.1% ·
ELDN
Eledon Pharmaceuticals
 Mar 20, 2026 BUY Strong Buy
+313.4% avg upside
11 analysts
$8.00
112.23% Upside
 +32.6% ·
PROK
ProKidney
 Jul 13, 2025 BUY Buy
+340.1% avg upside
12 analysts
$7.00
373.03% Upside
 -56.4% ·
KROS
Keros Therapeutics
 May 29, 2025 HOLD Strong Buy
+119.7% avg upside
21 analysts
 — -19.8% ·
FR:GNFT
Genfit
 Mar 31, 2025 BUY Strong Buy
+128.5% avg upside
5 analysts
$9.00
32.81% Downside
 +161.9% ·
GOSS
Gossamer Bio
 May 06, 2024 HOLD Buy
+3714.3% avg upside
17 analysts
 — +39.7% ·
RLMD
Relmada Therapeutics
 Jun 15, 2023 BUY Buy
+193.5% avg upside
15 analysts
$26.00
450.91% Upside
 +18.0% ·
LLY
Eli Lilly & Co
 Jul 22, 2022 HOLD Strong Buy
-14.8% avg upside
48 analysts
 — +42.2% ·
CFRXQ
ContraFect
 Jul 22, 2022 HOLD Buy
+1429699900.0% avg upside
10 analysts
 — · ·
DNTH
Dianthus Therapeutics
 Jul 22, 2022 HOLD Strong Buy
-11.9% avg upside
29 analysts
 — -57.0% ·
XERS
Xeris Pharmaceuticals
 Jul 22, 2022 HOLD Strong Buy
+14.6% avg upside
10 analysts
 — +68.9% ·
AXSM
Axsome Therapeutics
 Jun 27, 2022 BUY Strong Buy
+10.1% avg upside
29 analysts
$49.00
77.23% Downside
 +125.1% ·
EOLS
Evolus
 Jun 21, 2022 BUY Strong Buy
+76.4% avg upside
9 analysts
$15.00
84.80% Upside
 -28.8% ·
ACAD
ACADIA Pharmaceuticals
 Jun 17, 2022 HOLD Strong Buy
+24.3% avg upside
43 analysts
$27.00
8.23% Downside
 +23.4% ·
CABA
Cabaletta Bio
 May 24, 2022 BUY Strong Buy
+393.0% avg upside
16 analysts
$10.00
250.80% Upside
 +702.3% ·
ALKS
Alkermes
 May 24, 2022 BUY Strong Buy
-17.2% avg upside
34 analysts
$36.00
28.31% Downside
 +3.5% ·
HALO
Halozyme
 May 22, 2022 BUY Strong Buy
-36.0% avg upside
20 analysts
$52.00
48.87% Downside
 -21.1% ·
REGN
Regeneron
 May 22, 2022 BUY Strong Buy
-1.7% avg upside
58 analysts
$738.00
7.50% Downside
 +10.2% ·
ROIV
Roivant Sciences
 May 22, 2022 BUY Strong Buy
-1.6% avg upside
17 analysts
$6.00
83.48% Downside
 +164.7% ·
TBPH
Theravance Biopharma
 May 22, 2022 BUY Buy
+9.0% avg upside
18 analysts
$12.00
29.01% Downside
 +16.7% ·
VRTX
Vertex Pharmaceuticals
 May 22, 2022 HOLD Strong Buy
-15.5% avg upside
62 analysts
$265.00
49.50% Downside
 +26.7% ·
SNY
Sanofi
 May 22, 2022 BUY Strong Buy
+69.1% avg upside
20 analysts
$139.45
219.09% Upside
 -2.1% ·
NBIX
Neurocrine
 May 04, 2022 HOLD Strong Buy
+19.2% avg upside
37 analysts
$95.00
39.26% Downside
 +8.4% ·
ARQT
Arcutis Biotherapeutics
 Sep 21, 2021 BUY Strong Buy
+52.7% avg upside
14 analysts
$58.00
120.61% Upside
 -17.1% ·
DCF
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
 Aug 12, 2021 BUY Buy
+36700.1% avg upside
2 analysts
 — · ·
ACGP
Associated Capital Group
 May 07, 2021 BUY Strong Buy
+50.2% avg upside
9 analysts
$37.00
10.54% Upside
 +5.3% ·
TEVA
Teva Pharmaceutical
 Jul 10, 2019 HOLD Buy
-17.9% avg upside
39 analysts
 — +28.1% ·
IRWD
Ironwood Pharma
 Jul 10, 2019 HOLD Buy
+173.7% avg upside
23 analysts
 — -6.7% ·
TLPH
Talphera
 Jul 10, 2019 BUY Buy
+235.6% avg upside
15 analysts
 — · ·
BMY
Bristol-Myers Squibb
 May 29, 2019 HOLD Buy
-4.3% avg upside
42 analysts
$55.00
13.63% Downside
 +35.9% ·
LKFT
Lakefront Biotherapeutics
 Dec 13, 2018 BUY Buy
+277.1% avg upside
24 analysts
 — +94.6% ·
IRMD
Iradimed
 Nov 27, 2017 BUY Strong Buy
-5.1% avg upside
6 analysts
$19.00
78.26% Downside
 +112.8% ·
CRVS
Corvus Pharmaceuticals
 Aug 23, 2017 HOLD Strong Buy
+70.3% avg upside
14 analysts
 — -24.8% ·
BIIB
Biogen
 Aug 02, 2016 HOLD Strong Buy
+21.4% avg upside
52 analysts
$322.00
54.15% Upside
 -12.8% ·
PDSB
PDS Biotechnology
 Oct 26, 2015 BUY Strong Buy
+6181.2% avg upside
11 analysts
$29.00
11883.44% Upside
 · ·
MYGN
Myriad Genetics
 Feb 04, 2015 SELL Hold
+455.4% avg upside
24 analysts
$30.00
828.72% Upside
 -4.2% ·
ILMN
Illumina
 Jan 28, 2015 BUY Buy
-8.8% avg upside
31 analysts
$230.00
19.32% Upside
 -22.0% ·
GILD
Gilead Sciences
 Apr 14, 2014 BUY Strong Buy
-12.5% avg upside
66 analysts
 — +53.0% ·
A
Agilent
 Mar 05, 2013 BUY Strong Buy
+0.4% avg upside
33 analysts
$48.00
67.71% Downside
 +36.9% ·
🔒 51 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Vamil Divan — Frequently Asked Questions
How accurate are Vamil Divan's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Vamil's ratings were profitable over a one-year hold, with an average return of +19.4% per rating, or +13.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Vamil ranked on 13Foresight?
Vamil Divan is currently ranked #374 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Vamil cover?
Vamil most recently has ratings on SVRA, JBIO, ANIP, AMGN, INSM, PFE, TVTX, JNJ, MRK, ABBV, VALN, ELOX and 44 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.